The 28-day toxicity study of the nanoemulsion proved to be a safe media to deliver olmesartan. Improved penetration of olmesartan through BBB following oral nanoemulsion delivery. The developed nano-delivery pose higher potential to step towards its clinical application. Olmesartan nanoemulsion can be explored in memory dysfunction and brain ischemia.